• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAPTOPRIL Drug Record

  • Summary
  • Interactions
  • Claims
  • CAPTOPRIL chembl:CHEMBL1560 Approved

    Alternate Names:

    HYTENEZE 12.5
    CAPTOPRIL
    LOPRIL
    HYTENEZE 25
    KAPLON
    SQ-14225
    ECOPACE
    CAPTOMEX
    HYTENEZE 50
    NOYADA
    TENSOBON
    SA-333
    C09AA01
    CAPOTEN
    SQ -14225
    ACEPRIL
    ACEPRESS
    CAPTOPRYL
    CAPOTEN®
    L-CAPTOPRIL
    D-3-MERCAPTO-2-METHYLPROPANOYL-L-PROLINE
    CAPTOLANE
    HYPERTIL
    APOPRIL
    (2S)-1-[(2S)-2-METHYL-3-SULFANYLPROPANOYL]PYRROLIDINE-2-CARBOXYLIC ACID
    CAPTORIL
    LOPIRIN
    CP
    D-2-METHYL-3-MERCAPTOPROPANOYL-L-PROLINE
    GARRANIL
    TENSOPREL
    TENOSBON
    CAPTOPRILUM
    CESPLON
    DILABAR
    drugbank:01197
    rxcui:1998
    pubchem.compound:44093
    chembl:CHEMBL1560
    chemidplus:62571-86-2

    Drug Info:

    FDA Approval 1981
    Drug Class small molecule
    Drug Indications Antihypertensive Agents
    Drug Categories enzyme inhibitors
    Year of Approval 1981
    Drug Class antihypertensive agents
    Drug Categories agents causing angioedema
    Drug Categories agents causing hyperkalemia
    Drug Categories agents causing muscle toxicity
    Drug Categories antihypertensive agents indicated for hypertension
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories oat1/slc22a6 inhibitors
    Drug Categories oat1/slc22a6 substrates
    Drug Categories oat3/slc22a8 substrates
    Drug Categories p-glycoprotein inhibitors
    Drug Categories photosensitizing agents
    (6 More Sources)

    Publications:

    Reinhardt et al., 2002, Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP., Heart
    Okada et al., 2008, Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats., J. Pharmacol. Sci.
    Williams et al., 2005, Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models., Eur J Surg Oncol
    Yamamoto et al., 2008, Inhibitory profiles of captopril on matrix metalloproteinase-9 activity., Eur. J. Pharmacol.
    Ferreira de Oliveira F et al., 2016, Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease., Colomb Med (Cali)
    Kumakura et al., 1988, Role of bradykinin in the vascular permeability response induced by carrageenin in rats., Br. J. Pharmacol.
    Tzakos et al., 2006, The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme., Bioorg. Med. Chem. Lett.
    Marumo et al., 1987, Mechanisms for the inhibition of vasopressin-stimulated water flow by captopril in the toad bladder., Pharmacology
    Ogawa et al., 1985, No role for prostaglandins and bradykinin in the autoregulation of renal blood flow., Jpn. J. Pharmacol.
    Piepho, 2000, Overview of the angiotensin-converting-enzyme inhibitors., Am J Health Syst Pharm
    Song et al., 2002, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update., Clin Pharmacokinet
    Kumakura et al., 1987, Role of bradykinin generating and degrading systems in the vascular permeability response induced with kaolin in rats., J. Pharmacol. Exp. Ther.
    Volkan-Salanci B et al., 2009, Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus., J Renin Angiotensin Aldosterone Syst
    Andújar-Sánchez et al., 2007, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method., FEBS Lett.
    Dietze et al., 1987, [Captopril in hypertensive patients with type II diabetes mellitus]., Herz
    Metting et al., 1987, Enzymatic formation of angiotensins II and III in the hindlimb circulation of dogs., Can. J. Physiol. Pharmacol.
    Natesh et al., 2004, Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme., Biochemistry
    Felehgari V et al., 2011, ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria., Mol Cell Biochem
    Dalkas et al., 2010, Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme., J. Pept. Sci.
    Kiowski et al., 1982, Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation., Clin. Pharmacol. Ther.
    Suzuki et al., 1981, Converting enzyme inhibition and modulation of plasma renin activity with captopril in anesthetized rats., Arch Int Pharmacodyn Ther
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    O'Toole L et al., 1998, Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure., J Cardiovasc Pharmacol
    Todorov et al., 2003, Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes., FASEB J.
    Morinelli et al., 2002, Utilization of a radioimmunoassay to detect the generation of Arg-Pro-Pro-Gly-Phe, a stable endproduct of bradykinin metabolism (from cultured rat aortic smooth muscle cells exposed to bradykinin)., Int. Immunopharmacol.
    Regoli et al., 1986, Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels., Eur. J. Pharmacol.
    Jacobsen P et al., 1998, Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy., Kidney Int
    Mizuiri S et al., 1997, Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism., Nephron
    Hu et al., 1996, Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats., Zhongguo Yao Li Xue Bao
    Davis et al., 1996, Substance P and capsaicin-induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors., Br. J. Pharmacol.
    Mazzocchi et al., 1985, Effect of somatostatin on the zona glomerulosa of rats treated with angiotensin II or captopril: stereology and plasma hormone concentrations., J. Steroid Biochem.
    Brower et al., 2007, Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure., Am. J. Physiol. Heart Circ. Physiol.
    Prontera et al., 1999, Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma., Int. J. Cancer
    Yamamoto et al., 2010, Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy., Clin. Chim. Acta
    Byrd et al., 2007, Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema., J. Allergy Clin. Immunol.
    Liu et al., Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan., Clin. Exp. Hypertens.
    Veerasingham et al., 2005, Increased PI3-kinase in presympathetic brain areas of the spontaneously hypertensive rat., Circ. Res.
    Moriyama et al., 1997, Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction., Jpn. Circ. J.
    Thunnissen et al., 2002, Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors., FASEB J.
    Lasdun et al., 1989, Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone., J. Pharmacol. Exp. Ther.
    Moretti et al., 1997, Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats., J. Cardiovasc. Pharmacol.
    Fu et al., 2005, A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats., Eur. J. Pharmacol.
    Fan X et al., 2007, Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women., Clin Pharmacol Ther
    Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
    Ignjatovic T et al., 2002, Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor., J Biol Chem
  • CAPTOPRIL   ACE

    Interaction Score: 1.6

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    27546928 2839262 16889963 2442780 3937925 11030016 11929321 3320343 19286758 17618628 3325392 3038284 15236580 20830509 20014331 7042175 6275810 11752352 9869506 12424228 12489813 2875891 9551410 9069453 9863143 8864563


    Sources:
    NCI TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • CAPTOPRIL   ACE2

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17473847


    Sources:
    PharmGKB

  • CAPTOPRIL   SST

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2864479


    Sources:
    NCI

  • CAPTOPRIL   MMP2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17308006 10328230 12381651 19057128 15993560 20184869


    Sources:
    DrugBank

  • CAPTOPRIL   MMP9

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    12381651 19057128 15993560 18501888


    Sources:
    DrugBank

  • CAPTOPRIL   BDKRB1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11880373


    Sources:
    DrugBank

  • CAPTOPRIL   MMP12

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24074025


    Sources:
    DTC

  • CAPTOPRIL   GNRH1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2681686


    Sources:
    NCI

  • CAPTOPRIL   MYO9B

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10052650


    Sources:
    NCI

  • CAPTOPRIL   LTA4H

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    12207002


    Sources:
    DrugBank

  • CAPTOPRIL   SERPINE1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9152782


    Sources:
    NCI

  • CAPTOPRIL   CYP19A1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9268216


    Sources:
    NCI

  • CAPTOPRIL   AGTR1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19286758


    Sources:
    PharmGKB

  • CAPTOPRIL   NOS2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15680268


    Sources:
    NCI

  • CAPTOPRIL   DPP4

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17531305


    Sources:
    NCI

  • CAPTOPRIL   PIK3CG

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15662030


    Sources:
    NCI

  • CAPTOPRIL   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB01197

    • Version: 5.1.7

    Alternate Names:
    CAPTOPRIL DrugBank Drug Name
    62571-86-2 CAS Number
    Acepress Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories ace inhibitors and diuretics

    Publications:
    Brower et al., 2007, Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure., Am. J. Physiol. Heart Circ. Physiol.
    Prontera et al., 1999, Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma., Int. J. Cancer
    Reinhardt et al., 2002, Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP., Heart

  • TEND: CAPTOPRIL

    • Version: 01-August-2011

    Alternate Names:
    CAPTOPRIL Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 1981

    Publications:

  • TdgClinicalTrial: CAPTOPRIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antihypertensive Agents
    Drug Class small molecule
    FDA Approval 1981

    Publications:

  • NCI: CAPTOPRIL

    • Version: 14-September-2017

    Alternate Names:
    C340 NCI drug code

    Drug Info:

    Publications:
    Moretti et al., 1997, Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats., J. Cardiovasc. Pharmacol.
    Fu et al., 2005, A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats., Eur. J. Pharmacol.
    Byrd et al., 2007, Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema., J. Allergy Clin. Immunol.

  • DTC: CAPTOPRIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1560 ChEMBL Drug ID

    Drug Info:

    Publications:
    Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem

  • PharmGKB: captopril

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Fan X et al., 2007, Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women., Clin Pharmacol Ther
    Volkan-Salanci B et al., 2009, Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus., J Renin Angiotensin Aldosterone Syst
    Ferreira de Oliveira F et al., 2016, Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease., Colomb Med (Cali)

  • TTD: Captopril

    • Version: 2020.06.01

    Alternate Names:
    D0I0EG TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178101850

    • Version: 29-September-2020

    Alternate Names:
    CAPTOPRIL GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1560

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1560

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21